1-16 of 16
John Crowley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

Available to Purchase
Margaret von Mehren, Suzanne George, Michael C. Heinrich, Scott M. Schuetze, Jeffrey T. Yap, Jain Q. Yu, Amanda Abbott, Samuel Litwin, John Crowley, Martin Belinsky, Katherine A. Janeway, Jason L. Hornick, Douglas B. Flieder, Rashmi Chugh, Lori Rink, Annick D. Van den Abbeele
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1837–1845.
https://doi.org/10.1158/1078-0432.CCR-19-1069
Published: 15 April 2020
View article titled, Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
Open the PDF for Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study in another window
Journal Articles

Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design

Free
Shigeyuki Matsui, John Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (5): 994–1001.
https://doi.org/10.1158/1078-0432.CCR-17-1552
Published: 28 February 2018
View article titled, Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design
Open the PDF for Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design in another window
Includes: Supplementary data
Journal Articles

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

Free
Yogesh S. Jethava, Alan Mitchell, Joshua Epstein, Maurizio Zangari, Shmuel Yaccoby, Erming Tian, Sarah Waheed, Rashid Khan, Xenofon Papanikolaou, Monica Grazziutti, Michele Cottler-Fox, Nathan Petty, Douglas Steward, Susan Panozzo, Clyde Bailey, Antje Hoering, John Crowley, Jeffrey Sawyer, Gareth Morgan, Bart Barlogie, Frits van Rhee
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2665–2672.
https://doi.org/10.1158/1078-0432.CCR-15-2620
Published: 31 May 2017
View article titled, Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Open the PDF for Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants in another window
Includes: Supplementary data
Journal Articles

Conclusions of a seven-year translational research initiative: Defining and validating a molecular signature of high-risk multiple myeloma

Free
John Shaughnessy, Jr, Fenghuang Zhan, Bart Barington, John Crowley, Bart Barlogie
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): PR-2.
Published: 15 August 2014
View article titled, Conclusions of a seven-year translational research initiative: Defining and validating a molecular signature of high-risk multiple myeloma
Journal Articles

Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials

Free
Philip A. Philip, Kari Chansky, Michael LeBlanc, Lawrence Rubinstein, Lesley Seymour, S. Percy Ivy, Steven R. Alberts, Paul J. Catalano, John Crowley
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (16): 4176–4185.
https://doi.org/10.1158/1078-0432.CCR-13-2024
Published: 13 August 2014
View article titled, Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials
Open the PDF for Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials in another window
Journal Articles

Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine

Free
Shigeyuki Matsui, Richard Simon, Pingping Qu, John D. Shaughnessy, Jr, Bart Barlogie, John Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6065–6073.
https://doi.org/10.1158/1078-0432.CCR-12-1206
Published: 06 November 2012
View article titled, Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine
Open the PDF for Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine in another window
Journal Articles

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Free
Christoph J. Heuck, Jackie Szymonifka, Emily Hansen, John D. Shaughnessy, Jr, Saad Z. Usmani, Frits van Rhee, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, Clyde Bailey, Joshua Epstein, Antje Hoering, John Crowley, Bart Barlogie
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5499–5506.
https://doi.org/10.1158/1078-0432.CCR-12-0019
Published: 30 September 2012
View article titled, Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
Open the PDF for Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1 in another window
Includes: Supplementary data
Journal Articles

DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies

Free
Graham A. Colditz, John Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (22): 6971–6972.
https://doi.org/10.1158/1078-0432.CCR-11-1862
Published: 14 November 2011
View article titled, DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies
Open the PDF for DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies in another window
Journal Articles

Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents

Free
Antje Hoering, Mike LeBlanc, John Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 640–646.
https://doi.org/10.1158/1078-0432.CCR-10-1262
Published: 15 February 2011
View article titled, Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents
Open the PDF for Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents in another window
Journal Articles

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

Free
Lesley Seymour, S. Percy Ivy, Daniel Sargent, David Spriggs, Laurence Baker, Larry Rubinstein, Mark J. Ratain, Michael Le Blanc, David Stewart, John Crowley, Susan Groshen, Jeffrey S. Humphrey, Pamela West, Donald Berry
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1764–1769.
https://doi.org/10.1158/1078-0432.CCR-09-3287
Published: 14 March 2010
View article titled, The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Open the PDF for The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee in another window
Journal Articles

Multiple Histology Phase II Trials

Free
Michael LeBlanc, Cathryn Rankin, John Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (13): 4256–4262.
https://doi.org/10.1158/1078-0432.CCR-08-2069
Published: 01 July 2009
View article titled, Multiple Histology Phase II Trials
Open the PDF for Multiple Histology Phase II Trials in another window
Journal Articles

Randomized Phase II Designs

Free
Larry Rubinstein, John Crowley, Percy Ivy, Michael LeBlanc, Dan Sargent
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 1883–1890.
https://doi.org/10.1158/1078-0432.CCR-08-2031
Published: 16 March 2009
View article titled, Randomized Phase II Designs
Open the PDF for Randomized Phase II Designs in another window
Journal Articles

Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma

Free
Bart Burington, Bart Barlogie, Fenghuang Zhan, John Crowley, John D. Shaughnessy, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15): 4821–4829.
https://doi.org/10.1158/1078-0432.CCR-07-4568
Published: 01 August 2008
View article titled, Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma
Open the PDF for Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

Free
Jeffrey Haessler, John D. Shaughnessy, Jr., Fenghuang Zhan, John Crowley, Joshua Epstein, Frits van Rhee, Elias Anaissie, Mauricio Pineda-Roman, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, Guido Tricot, Bart Barlogie
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (23): 7073–7079.
https://doi.org/10.1158/1078-0432.CCR-07-0527
Published: 03 December 2007
View article titled, Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
Open the PDF for Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel

Free
Martin J. Edelman, Joseph I. Clark, Kari Chansky, Kathy Albain, Nirmala Bhoopalam, Geoffrey R. Weiss, Jeffrey K. Giguere, Karen Kelly, John Crowley, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 5022–5026.
https://doi.org/10.1158/1078-0432.CCR-04-0002
Published: 05 August 2004
View article titled, Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel
Open the PDF for Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel in another window
Journal Articles

Bronchioloalveolar Carcinoma: A Model for Investigating the Biology of Epidermal Growth Factor Receptor Inhibition

Free
David R. Gandara, Howard West, Kari Chansky, Angela M. Davies, Derick H. M. Lau, John Crowley, Paul H. Gumerlock, Fred R. Hirsch, Wilbur A. Franklin
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (12): 4205s–4209s.
https://doi.org/10.1158/1078-0432.CCR-040012
Published: 15 June 2004
View article titled, Bronchioloalveolar Carcinoma: A Model for Investigating the Biology of Epidermal Growth Factor Receptor Inhibition
Open the PDF for Bronchioloalveolar Carcinoma: A Model for Investigating the Biology of Epidermal Growth Factor Receptor Inhibition in another window